文献速递炎症性肠病消化内镜

波兰与捷克炎症性肠病三级中心:以较短及非炎性狭窄为主的患者中内镜下肠道扩张困难的风险因素

Risk factors for difficult endoscopic bowel dilation of predominantly shorter and noninflammatory strictures among patients with inflammatory bowel disease: findings from inflammatory bowel disease tertiary centers in Poland and Czech Republic.
PubMed 文献 · Gastrointest Endosc · 2025-03-03

这项回顾性多中心研究纳入861例因狭窄接受内镜下球囊扩张(EBD)的炎症性肠病(IBD)患者,评估困难EBD(定义为每年≥3次)的患病率、风险因素和临床结局。中位随访23.00个月期间,困难EBD占54.5%,最重要的可改变风险因素为吸烟、阿达木单抗(尤其谷浓度正常时)和乌司奴单抗治疗,维得利珠单抗和免疫抑制治疗为保护因素。

要点

  • 困难EBD(每年≥3次)在861例IBD狭窄患者中占54.5%,容易EBD占45.5%。
  • 困难EBD的最重要可改变风险因素为吸烟、阿达木单抗(尤其谷浓度正常时)和乌司奴单抗治疗。
  • 维得利珠单抗和免疫抑制治疗为保护因素;17.3%患者因EBD失败接受手术。

核心结论

  • 减少困难EBD应主要考虑其可改变的风险因素。
  • 需要同时评估透壁愈合的前瞻性研究来真正评估维得利珠单抗治疗、免疫抑制治疗和全肠外营养是否降低EBD风险。

研究设计与样本

  • 回顾性多中心研究,纳入861例因狭窄接受EBD治疗的IBD患者,来自波兰和捷克共和国的IBD三级中心。
  • 评估困难EBD(定义为每年≥3次)的风险因素。

主要发现

  • 中位(IQR)随访23.00(14.00-42.00)个月期间,容易EBD 392例(45.5%),困难EBD 489例(54.5%)。
  • EBD长期疗效(定义为>12个月无手术)在容易EBD中为392例(100%),在困难EBD中为457例(97.4%)(Cramer's V=.11;P=.004)。
  • 149例(17.3%)患者因EBD不成功接受手术。
  • 困难EBD最重要的可改变风险因素为吸烟、阿达木单抗治疗(尤其谷浓度正常时)和乌司奴单抗治疗;维得利珠单抗和免疫抑制治疗为保护因素。
  • 多变量逻辑回归分析显示模型拟合良好,全肠外营养和吸烟加重均呈保护作用(两者P<.001)。

关键数值与推荐

  • 困难EBD定义为每年≥3次。
  • EBD长期疗效定义为>12个月无手术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Intestinal strictures are a common and serious adverse event of inflammatory bowel disease (IBD). Endoscopic balloon dilation (EBD) is the first step in treatment to avoid surgery. The aim of this study was to assess the prevalence, risk factors, and clinical sequelae of difficult EBD. METHODS: This retrospective, multicenter study included 861 patients with IBD treated with EBD due to strictures. Risk factors for difficult EBD, defined as ≥3 per year, were evaluated. RESULTS: During a median (IQR) of 23.00 (14.00-42.00) months of follow-up, there were 392 (45.5%) easier EBDs performed, while difficult EBDs were performed in 489 (54.5%) cases. Long-term efficacy of EBD, defined as >12 months without surgery, was achieved in 392 (100%) easier EBDs versus 457 (97.4%) difficult EBDs (Cramer's V = .11; P = .004). However, 149 (17.3%) patients underwent surgery for unsuccessful EBD. The most important risk factors for difficult EBD, classified as modifiable, were smoking and treatment with adalimumab (especially if trough levels were normal) and ustekinumab. Vedolizumab and immunosuppressive therapy were identified as protective factors. Multivariable logistic regression analysis indicated good fit of the model to the data, pointing to a protective role for total parental nutrition and worsening of smoking (both, P < .001). CONCLUSIONS: Reduction of difficult EBDs should be considered primarily in the context of their modifiable risk factors. Prospective studies with simultaneous evaluation of transmural healing are needed to truly assess whether vedolizumab treatment, immunosuppressive therapy, and total parenteral nutrition reduce the risk of EBD.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Lewandowski K, Lukas M, Kaniewska M, et al. Risk factors for difficult endoscopic bowel dilation of predominantly shorter and noninflammatory strictures among patients with inflammatory bowel disease: findings from inflammatory bowel disease tertiary centers in Poland and Czech Republic. Gastrointest Endosc. 2025. PMID: 40044092. doi:10.1016/j.gie.2025.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。